Cell Line Origin
Human Caucasian bronchioalveolar carcinoma
Cell Line Description
NCI-H322 was derived in 1981 from a primary bronchioalveolar carcinoma of the lung from a 52 year old male taken prior to treatment. Ultrastructural studies of this non-small cell carcinoma cell line demonstrated the presence of cytoplasmic structures characteristic of Clara cells. NCI-H322 do not express UDP-glucuronosyltransferase, but are reported to express glutathione-S-transferase and phenol sulfotransferase. Expression of protein and RNA of SP-A, the major surfactant-associated protein was detected. The cells produce tumours in athymic mice.
Application
NCI-H322 has been used to study the preclinical antitumor efficacy of BAY 1129980, which is an anti-C4.4A (Ly6/PLAUR domain-containing protein 3 precursor-LYPD3) antibody–drug conjugate for the treatment of non–small cell lung cancer.
Test system for evaluating cytotoxicity and genotoxicity of chemicals to human lung
Culture Medium
RPMI 1640 + 2mM Glutamine + 5-10% Foetal Bovine Serum (FBS).
Subculture Routine
Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 1-3x10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
biological source: human lung (cervical node metastasis). description: Human Caucasian bronchioalveolar carcinoma. growth mode: Adherent. karyotype: Not specified. morphology: Not specified. products: Not specified. receptors: Not specified. technique(s): cell culture | mammalian: suitable. relevant disease(s): metastasis. shipped in: dry ice. storage temp.: −. 196°C.- UPC:
- 51162706
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 95111734-1VL
